Aptose Biosciences (NASDAQ:APTO;TSX:APS), a clinical-stage oncology stock, reports dose-escalation approval for tuspetinib, its drug candidate to treat newly diagnosed acute myeloid leukemia ・Dosing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback